← Leaderboards
Dennis Larry Kolson
University Of Pennsylvania
$16,900,832
Attributed
$18,655,859
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,655,859 · 11
By mechanism
R01$15,963,295 · 6
P01$1,411,192 · 1
P50$804,626 · 1
M01$342,636 · 2
R29$134,110 · 1
Top collaborators
- Anna Aldovini6 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- George M Shaw$56,045,759
- Francisco A Gonzalez-Scarano$10,891,253
- Mirko Paiardini$32,628,549
- Kelly L Jordan-Sciutto$26,892,677
- Katharine June Bar$15,418,177
Others in their field
Top investigators on “Macrophage”
- Craig B Thompson · Sloan-Kettering Inst Can Research$41,669,179
- Howard Eliot Gendelman · Children'S Memorial Hospital (Chicago)$41,668,744
- Selwyn M Vickers · University Of Alabama At Birmingham$40,969,055
- Alan A Aderem · University Of Washington$38,969,733
- Alan Richard Tall · Columbia University Health Sciences$38,053,695
- John S Condeelis · Yeshiva University$33,855,255
Research focus
MacrophageHiv InfectionsAids Dementia ComplexResponseBrainIn VitroGlutamatesMonocytePathway InteractionsNeuroprotectionAstrocytesNeuronsMacrophage ActivationCellsNeurocognitiveNeurotoxinsApoptosisAntioxidantsNeurotoxicityLinkMacaca MulattaImmune ActivationDisease ProgressionMediating
Grant awards (48)
Protection against early SIV brain injury with adjunctive therapy to cART$790,121
R01 · FY2025 · NS · contact PI
Protection against early SIV brain injury with adjunctive therapy to cART$801,050
R01 · FY2024 · NS · contact PI
Protection against early SIV brain injury with adjunctive therapy to cART$814,050
R01 · FY2023 · NS · contact PI
Protection against early SIV brain injury with adjunctive therapy to cART$854,805
R01 · FY2022 · NS · contact PI
Regulation of Heme Oxygenase in HIV/HAND Pathogenesis$555,412
R01 · FY2020 · MH · contact PI
Regulation of Heme Oxygenase in HIV/HAND Pathogenesis$559,703
R01 · FY2019 · MH · contact PI
Regulation of Heme Oxygenase in HIV/HAND Pathogenesis$559,703
R01 · FY2018 · MH · contact PI
Oxidative Stress, Immune Activation, and Therapeutic Targeting in HIV/HAND$373,428
R01 · FY2018 · MH · contact PI
Regulation of Heme Oxygenase in HIV/HAND Pathogenesis$559,703
R01 · FY2017 · MH · contact PI
Oxidative Stress, Immune Activation, and Therapeutic Targeting in HIV/HAND$373,428
R01 · FY2017 · MH · contact PI
Regulation of Heme Oxygenase in HIV/HAND Pathogenesis$651,741
R01 · FY2016 · MH · contact PI
Oxidative Stress, Immune Activation, and Therapeutic Targeting in HIV/HAND$522,974
R01 · FY2016 · MH · contact PI
Pathways of HIV neurodegeneration and dimethyl fumarate (DMF/MMF) neuroprotection$670,774
R01 · FY2015 · MH · contact PI
Oxidative Stress, Immune Activation, and Therapeutic Targeting in HIV/HAND$519,471
R01 · FY2015 · MH · contact PI
Pathways of HIV neurodegeneration and dimethyl fumarate (DMF/MMF) neuroprotection$690,994
R01 · FY2014 · MH · contact PI
Oxidative Stress, Immune Activation, and Therapeutic Targeting in HIV/HAND$548,224
R01 · FY2014 · MH · contact PI
Pathways of HIV neurodegeneration and dimethyl fumarate (DMF/MMF) neuroprotection$676,854
R01 · FY2013 · MH · contact PI
Pathways of HIV neurodegeneration and dimethyl fumarate (DMF/MMF) neuroprotection$724,652
R01 · FY2012 · MH · contact PI
Pathways of HIV neurodegeneration and dimethyl fumarate (DMF/MMF) neuroprotection$395,964
R01 · FY2012 · MH · contact PI
HIV Neural Apoptosis: Mechanisms, Pathways & Protection$394,884
R01 · FY2011 · NS · contact PI
Pathways of HIV neurodegeneration and dimethyl fumarate (DMF/MMF) neuroprotection$350,816
R01 · FY2011 · MH · contact PI
HIV Neural Apoptosis: Mechanisms, Pathways & Protection$390,936
R01 · FY2010 · NS · contact PI
Astrocyte Activation, Dysfunction & Apoptosis in HAD$403,447
P50 · FY2009 · NS · contact PI
HIV Neural Apoptosis: Mechanisms, Pathways & Protection$394,884
R01 · FY2009 · NS · contact PI
Astrocyte Activation, Dysfunction & Apoptosis in HAD$401,179
P50 · FY2008 · NS · contact PI
HIV Neural Apoptosis: Mechanisms, Pathways & Protection$394,903
R01 · FY2008 · NS · contact PI
Astrocyte Activation, Dysfunction & Apoptosis in HAD$418,377
P01 · FY2007 · NS · contact PI
HIV Neural Apoptosis: Mechanisms, Pathways & Protection$409,231
R01 · FY2007 · NS · contact PI
Astrocyte Activation, Dysfunction & Apoptosis in HAD$387,129
P01 · FY2006 · NS · contact PI
HIV Neural Apoptosis:Mechanisms, Pathways & Protection$367,592
R01 · FY2006 · NS · contact PI
Astrocyte Activation, Dysfunction &Apoptosis in HAD$398,636
P01 · FY2005 · NS
HIV Neural Apoptosis:Mechanisms, Pathways &Protection$376,438
R01 · FY2005 · NS
AACTG 5090: SELEGILINE FOR TREATMENT OF HIV-ASSOCIATED COGNITIVE IMPAIRMENT$39,582
M01 · FY2005 · RR
HIV Neural Apoptosis:Mechanisms, Pathways &Protection$376,438
R01 · FY2004 · NS
AACTG 5090: SELEGILINE FOR TREATMENT OF HIV-ASSOCIATED COGNITIVE IMPAIRMENT$29,648
M01 · FY2004 · RR
HIV Neural Apoptosis:Mechanisms, Pathways &Protection$376,438
R01 · FY2003 · NS
ACTG 301--MEMANTINE FOR AIDS DEMENTIA COMPLEX WITH ANTIRETROVIRAL THERAPY$124,146
M01 · FY2002 · RR
REVERSE PSEUDOTYPE HIV 1 TARGETING OF NEURAL CELLS$103,525
P01 · FY2002 · NS
CHEMOKINES AND NEURONAL/GLIAL FUNCTION IN AIDS DEMENTIA$247,255
R01 · FY2001 · NS
ACTG 301--MEMANTINE FOR AIDS DEMENTIA COMPLEX WITH ANTIRETROVIRAL THERAPY$124,146
M01 · FY2001 · RR
REVERSE PSEUDOTYPE HIV 1 TARGETING OF NEURAL CELLS$103,525
P01 · FY2001 · NS
ACTG 301--MEMANTINE FOR AIDS DEMENTIA COMPLEX WITH ANTIRETROVIRAL THERAPY$0
M01 · FY2001 · RR
CHEMOKINES AND NEURONAL/GLIAL FUNCTION IN AIDS DEMENTIA$240,429
R01 · FY2000 · NS
NEURONAL CELL FUNCTIONS IN AIDS DEMENTIA--A UNIQUE MODEL$134,110
R29 · FY2000 · NS
ACTG 301--MEMANTINE FOR AIDS DEMENTIA COMPLEX WITH ANTIRETROVIRAL THERAPY$25,114
M01 · FY2000 · RR
ACTG 301--MEMANTINE FOR AIDS DEMENTIA COMPLEX WITH ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
REVERSE PSEUDOTYPE HIV 1 TARGETING OF NEURAL CELLS$0
P01 · FY2000 · NS
ACTG 301--MEMANTINE FOR AIDS DEMENTIA COMPLEX WITH ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR